Author:
Flieger Dimitri,Hainke Sabine,Fischbach Wolfgang
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference3 articles.
1. Larson AM (2003) Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 36:149–158
2. Kindler HL, Karrison T, Lu C, Gandara DR, Stevenson J, Krug L, Janne P, Guterz TL, Stadler WM, Vokes EE (2005) A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Am soc Clin Oncol 24:7019 (abstract)
3. Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90:818–828
Cited by
102 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献